Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS

Classifica tra le azioni #17277
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-88.86%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)

Categoria

Healthcare
Storico del prezzo dell'azione per Regulus Therapeutics Inc. (RGLS)
Prezzo di chiusura più alto: $73.27 il 2024-11-01

Prezzo di chiusura più basso: $21.00 il 2010-04-01
Storico del prezzo dell'azione di Regulus Therapeutics Inc. dal 2010 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 113.53%
2023 140.97%
2022 -61.38%
2021 -67.58%
2020 -13.91%
2019 22.71%
2018 12.94%
2017 104.37%
2016 -25.20%
2015 -38.37%
2014 34.13%
2013 93.41%
2012 67.05%
2011 2.83%
2010 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$518.20 21.57%
US
$243.77 786.76%
US
$138.33 -3.31%
AU
$879.20 5.32%
NL
$752.87 7.40%
CH